Eric Schmidt

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today unveiled new pharmacokinetic ("PK") data from its Phase 2a Eosinophilic Esophagitis ("#EoE") program. Management believes these data underscore the unique capabilities of Eupraxia's proprietary DiffuSphere™ platform technology, which aims to provide precise, localized, safe, and effective long-lasting drug delivery. Most conventional drugs release in a pattern characterized by steep peaks and rapid declines in drug concentration, where peaks often lead to negative side effects, and troughs result in reduced efficacy. In contrast, #DiffuSphere™ is a unique microsphere that is designed to enable #precisedrugrelease into target tissues with a flat, stable, and long-lasting profile, minimizing potential adverse events associated with high-dose systemic delivery. What sets DiffuSphere™ apart is its composition: a pure drug crystal encased in a microns-thick polymer shell. Eupraxia's #proprietary #technology uses this polymer to precisely control a drug's release, ensuring high drug concentrations in the target tissues while minimizing exposure to the rest of the body. This #innovative approach has been observed in Eupraxia's clinical programs, demonstrating precision, tolerability, and extended duration of delivering fluticasone propionate ("FP") directly to the intended tissues for EoE and knee osteoarthritis ("OA") patients. #biotech #pharma #investing #mergers https://lnkd.in/gX8fii4X

1

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762 Newsfile Corp. Newsfile Corp Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma Marlborough, Massachusetts--(Newsfile Corp. - January 13, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced pathologic responses for patients enrolled in the 2nd cohort, which includes 2 patients with a complete response or 100% tumor clearance. Phio's ongoing Phase 1b clinical study (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2 and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma and Stage 4 Merkel cell carcinoma. Of the patients enrolled to date, 6 patients were diagnosed with cutaneous squamous cell carcinoma and 1 patient was diagnosed with metastatic melanoma. At Day 36 (tumor excision), while patients in the first cohort had stable disease, results are now available for the 4 patients who completed treatment in the 2nd cohort: Complete response (100% tumor clearance) is reported for 2 patients with cutaneous squamous cell carcinoma. Partial response (90% tumor clearance) is reported for 1 patient with cutaneous squamous cell carcinoma and 1 patient had stable disease, having not progressed. There have been no dose-limiting toxicities, or clinically relevant treatment-emergent adverse events in the patients receiving intratumoral PH-762. The intratumoral injections have been well tolerated. "We are pleased and encouraged by the profound tumor response in the second dose cohort, coupled with reassuring safety data," said Mary Spellman MD, Phio's acting Chief Medical Officer. "We look forward to continued enrollment which will permit assessment of higher dose concentrations of PH-762." "These positive results in the early stages of dose escalation offer promise for our vision, 'striving for a cancer free future' using INTASYL technology" said Robert Bitterman, CEO of Phio Pharmaceuticals.

2

NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a #lifescience portfolio company dedicated to bringing breakthrough treatments to patients in #oncology, #autoimmunediseases, and #womenshealth, today announced that it is expanding its bifunctional #antibody #pipeline to include a novel PD-1 x VEGF tetravalent #bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) and other solid tumors. NAYA is leveraging its proprietary FLEX antibody platform and further optimizing its design through a #partnership with #MabSilico, an #artificialintelligence & deep technology-focused company, to accelerate the development of new best-in-class candidates for validated therapeutic targets. “We are excited to add a novel, #AI-optimized PD-1 x VEGF therapeutic candidate to our pipeline of best-in-class bifunctional antibodies,” President Dr. Daniel Teper. “NAYA’s bifunctional format has demonstrated the ability for synergistic dual-targeting activity, resulting in the potential to unlock clinical response in solid tumors.”

6

Eupraxia Pharmaciticals (NASDAQ: EPRX) One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks. At 24 weeks, the fourth cohort experienced the largest average reduction in SDI scores of all cohorts to date. The fifth cohort continued to show improved patient outcomes with the greatest percentage change in histology (EoEHSS2) scores of any cohort to date. Both the mean reduction in Peak Eosinophil Counts (PEC3)at four biopsy sites and the percent change in histology (EoEHSS2) scores showed a clear dose response across Cohorts 3 to 5, with Cohort 5 showing the greatest response. No serious adverse events reported in any of the five cohorts to date. Cohort 6 is now fully enrolled and dosed, with 12-week data anticipated in Q1 2025.

5

Join our webinar tomorrow at 12:00 PM to see how Allysta Pharmaceuticals is developing a completely new treatment for Duchenne Muscular Dystrophy, a genetic disease that affects men starting in childhood. https://hubs.la/Q02tLLgY0

1

J&J $JNJ buys Intra-Cellular $ITCI in $14.6 billion deal, delving further into central nervous system disorders #Biotech #healthcare #mergers #acquisitions #JPM2025 #CNS #investing $IBB $XBI $SER $LTRN

5

Decentralized (virtual) clinical trials and remote patient monitoring are powerful, innovative pharma tools. But they are not simple for pharma to use. Adoption is slow for a myriad of reasons! #DCT #RPM #virtualtrials #remotepatientmonitoring

6

Watch the full video to hear more about a unique strategy and how it fuels innovation! "Indaptus' approach to patents" Chief Operating Officer, Walt Linscott, discusses Indaptus Therapeutics' robust approach to #patents and trade secrets, highlighting how they ensure full protection of our #Decoy #technology across the globe. Learn how they safeguard their technology and ensure long-term protection for our advancements in oncology, virology, and beyond. This is key to their mission of developing breakthrough treatments for cancer and other diseases. $INDP $MRK $IBB $XBI #IP #oncology #cancer #waltlinscott #USMC #IndaptusTherapeutics #PatentStrategy #Biotech #CancerResearch #IPprotection #Decoy20 #Oncology #Virology #ColonCancer https://lnkd.in/g_SRdJkK

2

MassBioDrive harnesses the power of MassBio’s global life sciences network to help new founders launch their biotech startups. We announced our #MassBioDrive Spring 2024 Cohort back in March, and as we near the end of the eight-week program, we are highlighting our five emerging biotech companies chosen to participate. Today, please meet Nucyrna Therapeutics! Q: Tell us about your company and what you’re developing. What are you most excited about? A: Nucyrna Therapeutics aims to redefine RNA-targeting therapeutics by co-targeting nuclear and cytoplasmic RNAs. Nucyrna’s oligonucleotide platform enables a superior therapeutics index for single RNA silencing and can serve as a dual-RNA targeting platform. With our lead programs targeting ALS, we are working to address the huge unmet medical needs in CNS disorders in our rapid aging society. I’m most excited about developing disease-modifying therapies for these patients. Q: What advice do you have for other biotech companies just getting started? A: It’s never too early to talk to advisors such as serial entrepreneurs for advice. MassBioDrive is an amazing mentorship program helping entrepreneurs figure out challenges at the early stage. Q: What has been most impactful or surprising to you since joining the MassBioDrive program? A: The most impactful thing is we have decided our leading two programs based on our oligonucleotide platform technology with the guidance from MassBioDrive program mentors. Learn more about Nucyrna Therapeutics: https://www.nucyrnatx.com/ Learn more about MassBioDrive: https://lnkd.in/eAEMRZ-b Damon (Feng) Wang, PhD

30

MassBioDrive harnesses the power of MassBio’s global life sciences network to help new founders launch their biotech startups. We announced our #MassBioDrive Spring 2024 Cohort back in March, and as we near the end of the eight-week program, we are highlighting our five emerging biotech companies chosen to participate. Today, please meet Anita Scheuber and Hestia Therapeutics! Q: Tell us about your company and what you’re developing. What are you most excited about? A: At Hestia, we are developing the aNKor platform of tri-specific, tri-funtional immunocytokines that engage the adaptive AND innate immune system to very effectively attack cancer cells. Our approach is a targeted delivery of potent cytokines into the tumor microenvironment that is safer for patients compared to naked cytokines. Q: What advice do you have for other biotech companies just getting started? A: Surround yourself with a diverse group of people that bring industry relevant expertise to complement your own. Q: What has been most impactful or surprising to you since joining the MassBioDrive program? A: The Biotech hub in the Boston area remains strong, innovative and daring - it is just fantastic to learn through the MassBioDrive program that the immense resources, support and entrepreneurship still exists. It is truly inspiring and humbling to receive all that encouragement. Learn more about Hestia Therapeutics: https://hestiatx.com/ Learn more about MassBioDrive: https://lnkd.in/eAEMRZ-b

17

MassBio CEO & President Kendalle Burlin O'Connell, Esq. recently spoke with Adil Ali, MD and Onyx about representing the world's most consequential life sciences ecosystem, MassBio's Vision 2030 strategic roadmap, programs like #MassBioDrive and BioversityMA, and more. Onyx's in-depth report, Vital Signs: Future of Healthcare, will appear in Fortune magazine in December ahead of JPM Week. 🔗: https://lnkd.in/eVkggiwv

35

1 Comment

In September, the results of the Phase III trial of biospecific antibody Ivenescimab delivering a meaningful improvement over Merck’s Keytruda in lung cancer sent Summit Therapeutics (NASDAQ: SMMT) stock soaring. However, few paid attention to the originator of the PD-1/VEGF targeting asset, Chinese biotech Akeso Bio. Akeso represents a cohort of emerging innovative drug companies from China, working at impressive speed to deliver advancements in patient care and next-generation therapeutics with global ambition. #deeptech #chinesedeeptech #bosonventures #Ivenescimab #biotech #immuology

7

#TeamZura will participate in two investor conferences in June:​ 🔶Jefferies Global Healthcare Conference​ 🔶Oppenheimer & Co. Inc. Novel Targets in Immunology Summit​ Join us as we cover the latest corporate updates and pipeline developments. ​ Additional details can be found here: https://lnkd.in/etqVYAdw #InvestorRelations #Biotech #ZuraUpdates

26

Soligenix, Inc., a late-stage biopharmaceutical company focused on rare diseases, is participating in Spartan Capital Securities' inaugural investor conference on November 4th at the Pierre Hotel in New York. Christopher J. Schaber, PhD, President and CEO of Soligenix, expressed delight at the opportunity to present the company's accomplishments and future plans as it advances its rare disease pipeline. The conference, organized with B2i Digital, features over 30 companies, panel discussions, one-on-one meetings, and networking sessions. 'We're privileged to welcome Soligenix and showcase their accomplishments to our 950K+ sophisticated investor community across social media,' said David Shapiro, CEO of @b2idigital. John D. Lowry, Founder and CEO of @spartancapsec, emphasized the event's significance in commemorating Spartan Capital's 17 years in the capital markets and fostering connections between companies and investors. #investorrelations #biotechnology #rarediseases #soligenix #spartancapital #b2idigital

1

PTC was excited to learn, share and collaborate with other leading RNA experts at the recent 7th Annual RNA-Targeted Drug Discovery & Development Summit in Boston, MA, and the RNA at the Bench and Bedside IV conference in La Jolla, CA. Anu Bhattacharyya, Kerstin Effenberger, and Marla Weetall from our research team presented on ways PTC is leveraging its leading splicing platform to identify promising therapies for rare diseases with high unmet need. Learn more about our splicing platform here: https://bit.ly/4fi4w6L

135

1 Comment

Lantern Pharma Inc. (NASDAQ: LTRN), an #artificialintelligence #AI company dedicated to developing #cancertherapies and transforming the cost, pace, and timeline of #oncology #drugdiscovery and development, today announced that the #FDA has granted #FastTrack Designation for investigational drug candidate, LP-184, for treatment of #Glioblastoma. LP-184 is currently in a Phase 1A clinical trial designed to evaluate the safety and tolerability of the synthetically lethal investigational drug candidate in a broad range of solid tumors, including Glioblastoma (#GBM). LP-184 was optimized and advanced in part with Lantern’s AI platform, #RADR®, to aid in the validation of mechanisms that could be exploited in the clinical setting to eradicate challenging cancers, and uncover insights in targeted patient populations. RADR® is Lantern’s #AIplatform for #cancertherapy discovery, development and rescue with over 100 billion data points and aiding in the development of both Lantern’s portfolio and development initiatives with Lantern’s collaborators. #biotech #acquisition #IPO #venturecapital #privateequity #lifesciences

3

Appreciate John Glasspool’s op/ed in the Boston Business Journal. He brings the perspective of a CEO of a Cambridge-based #biotech, MassBio member Anthos Therapeutics, to the debate over the White House’s plans to use Bayh-Dole as a blunt instrument to force price controls. The reality is that any effort to use “march in” rights like this would hurt innovation, chill the collaborative relationship between research institutes and small biotechs (which are the lion’s share of Massachusetts’ industry) when it comes to advancing early science, and do nothing to address the price of drugs. You can’t argue with Bayh-Dole’s success: 6 million jobs, $2 trillion in economic output, thousands of startups, and 200+ drugs and vaccines. As John points out, we can’t go back to a time when science sat on shelves instead of getting into medicine cabinets. https://lnkd.in/ezkNndKA cc: The Bayh-Dole Coalition

32

3 Comments

Our CEO Michael Nally spoke at MassBio's State of Possible Conference with Barry Greene of Sage Therapeutics, Sharon Cunningham of Shorla Oncology, and Daphne Zohar of Seaport Therapeutics, moderated by Douglas Banks of Boston Business Journal. The panel explored Massachusetts' success in the life science industry—a story of innovation and resilience. These leaders discussed how they have survived and thrived through significant challenges. In a blog entry for MassBio, Mike notes: "By spearheading the transition from trial-and-error to programable, precision-based drug development, Massachusetts is reshaping the future of healthcare to better serve patients, the ecosystem, and the economy." Learn more about the panel, including a replay: https://lnkd.in/eHanbnQF #GenerativeAI I #ProteinEngineering 

46

1 Comment